RHOA and nasopharyngeal carcinoma: Tetrandrine was also reported to inhibit migration and invasion of human nasopharyngeal carcinoma dependent of MAPK and RhoA signaling pathways, suggesting its potential development in the application of anticancer agents for nasopharyngeal carcinoma therapy [6].